{"pmid":32361169,"pmcid":"PMC7194813","title":"Why not consider an endothelin receptor antagonist against SARS-CoV-2?","text":["Why not consider an endothelin receptor antagonist against SARS-CoV-2?","Med Hypotheses","Javor, S","Salsano, A","32361169"],"journal":"Med Hypotheses","authors":["Javor, S","Salsano, A"],"date":"2020-05-04T11:00:00Z","year":2020,"_id":"32361169","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1016/j.mehy.2020.109792","locations":["endothelin"],"topics":["Treatment"],"weight":1,"_version_":1666138495546032129,"score":9.490897,"similar":[{"pmid":32360293,"pmcid":"PMC7162760","title":"Endothelin receptor antagonists for pulmonary arterial hypertension and COVID-19: Friend or foe?","text":["Endothelin receptor antagonists for pulmonary arterial hypertension and COVID-19: Friend or foe?","J Heart Lung Transplant","Badagliacca, Roberto","Sciomer, Susanna","Petrosillo, Nicola","32360293"],"journal":"J Heart Lung Transplant","authors":["Badagliacca, Roberto","Sciomer, Susanna","Petrosillo, Nicola"],"date":"2020-05-04T11:00:00Z","year":2020,"_id":"32360293","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1016/j.healun.2020.04.007","locations":["Endothelin"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138495561760770,"score":72.36002},{"pmid":32462717,"title":"COVID-19: Consider IL6 receptor antagonist for the therapy of cytokine storm syndrome in SARS-CoV-2 infected patients.","text":["COVID-19: Consider IL6 receptor antagonist for the therapy of cytokine storm syndrome in SARS-CoV-2 infected patients.","COVID-19 leads to mortality of several patients and the cytokine storm is reportedly critical in the patients. In order to reduce the cytokine storm, we would like to propose the IL6 receptor antagonist therapy for the COVID-19 patients. Two humanized monoclonal antibodies are in clinical trial following IL6R antagonist therapies namely tocilizumab and sarilumab. However, researchers and physicians should look for more IL6 receptor antagonists for the therapy of cytokine storm syndrome SARS-CoV-2 infected persons to enhance the therapeutic options for cytokine storm. This article is protected by copyright. All rights reserved.","J Med Virol","Chakraborty, Chiranjib","Sharma, Ashish Ranjan","Bhattacharya, Manojit","Sharma, Garima","Lee, Sang-Soo","Agoramoorthy, Govindasamy","32462717"],"abstract":["COVID-19 leads to mortality of several patients and the cytokine storm is reportedly critical in the patients. In order to reduce the cytokine storm, we would like to propose the IL6 receptor antagonist therapy for the COVID-19 patients. Two humanized monoclonal antibodies are in clinical trial following IL6R antagonist therapies namely tocilizumab and sarilumab. However, researchers and physicians should look for more IL6 receptor antagonists for the therapy of cytokine storm syndrome SARS-CoV-2 infected persons to enhance the therapeutic options for cytokine storm. This article is protected by copyright. All rights reserved."],"journal":"J Med Virol","authors":["Chakraborty, Chiranjib","Sharma, Ashish Ranjan","Bhattacharya, Manojit","Sharma, Garima","Lee, Sang-Soo","Agoramoorthy, Govindasamy"],"date":"2020-05-29T11:00:00Z","year":2020,"_id":"32462717","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1002/jmv.26078","keywords":["cytokine storm","il6r antagonist","sarilumab","therapeutic option","tocilizumab"],"e_drugs":["tocilizumab","sarilumab"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1668079521235992576,"score":50.98238}]}